Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope.

BioNTech found runaway success during the COVID-19 pandemic when its Pfizer-partnered mRNA vaccine propelled the biotech to new heights. But now, with demand for the vaccine substantially lower and revenues way down in the first half of 2024, the pandemic darling is hedging its bets that an oncology pipeline will pay off in the coming years.